HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: EJE-07-0792v1 158/6/935    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Cassier, P. A Articles by Lombard-Bohas, C. PubMed PubMed Citation Articles by Cassier, P. A Articles by Lombard-Bohas, C.

Mifepristone for ectopic ACTH secretion in metastatic endocrine carcinomas: report of two cases.

¹ Unité de Jour d'Oncologie Médicale Multidisciplinaire and ² Service d'Endocrinologie, Hôpital Edouard Herriot, Lyon, 5 Place d'Arsonval, 69003, France³ Service de Gastroenterologie, Clinique Saint Jean, 69008 Lyon, France⁴ Service de Gastoentérologie , Fédération des Spécialtités Digestives, Hôpital Edouard Herriot, 5 Place d'Arsonval, 69003, Lyon, France and ⁵ Service d'Oncologie, Fédération des Spécialtités Digestives, Hôpital Edouard Herriot, 5 Place d'Arsonval, 69003 Lyon, France

(Correspondence should be addressed to C Lombard-Bohas; Email: catherine.lombard{at}chu-lyon.fr)

Abstract

Ectopic adrenocorticotropin secretion (EAS) remains a therapeutic challenge whenever the tumor responsible for the syndrome is not amenable to curative resection. Two cases of EAS related to metastatic foregut-derived endocrine carcinomas led us to use mifepristone, an antagonist of both progesterone and glucocorticoids. Mifepristone clearly improved skin lesions and diabetes associated with hypercorticism. The beneficial effect lasted for about 10 months. In both cases, recurrent hypertension and hypokalemia eventually required adrenalectomy.